CAR-T cell therapy for relapsed or refractory acute myeloid leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of CAR-T cell therapy that targets two proteins on leukemia cells (called CLL1 and CD33). The goal is to help people with acute myeloid leukemia that has relapsed or not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have acute myeloid leukemia that has come back or hasn't gotten better after at least one prior treatment.
- You are generally active and able to care for yourself (ECOG score of 0, 1, or 2).
- Your blood counts are within certain limits, and your kidney and liver functions are adequate.
- You are able to undergo a procedure to collect your white blood cells (apheresis).
- You do not have active infections, other recent cancers, or serious medical conditions that would make the treatment unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that uses your own immune cells, modified in the lab to find and attack leukemia cells. It's for people with AML that has come back or hasn't responded to standard treatment, and it may be followed by a stem cell transplant to help prevent the cancer from returning.
This study tests a new treatment that uses your own immune cells (called CAR-T cells) to fight leukemia, followed by a stem cell transplant to help rebuild your immune system. It is designed for people with acute myeloid leukemia (AML) that has not gone away or has come back after standard treatment.
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
This trial tests a new type of cell therapy, called CAR-T, that uses your own immune cells to find and attack leukemia cells. It's designed for people whose AML has come back or hasn't responded to standard treatments. The cells are modified to target a protein called CD33 on leukemia cells.
This trial tests an investigational therapy (CT1390B) for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. It aims to see if the therapy is safe and helps patients with a specific marker called CLL-1.
This study tests a universal CAR-T cell therapy for acute myeloid leukemia (AML), a type of blood cancer. The treatment uses specially engineered immune cells to target leukemia cells with certain markers, and the trial aims to see if it is safe and effective for patients whose leukemia has not responded to standard treatments.
Hear when a new AML (Acute Myeloid Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.